$314 Million is the total value of Knott David M Jr's 180 reported holdings in Q1 2022. The portfolio turnover from Q4 2021 to Q1 2022 was 100.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| ACQRW | Exit | Independence Holdings Warrants | $0 | – | -1,900 | -100.0% | -0.01% | – |
| GE | Exit | General Electric | $0 | – | -300 | -100.0% | -0.01% | – |
| Exit | Macquire Infrastructure Corp | $0 | – | -11,350 | -100.0% | -0.01% | – | |
| PRTS | Exit | Carparts.com Inc. | $0 | – | -3,700 | -100.0% | -0.01% | – |
| ZYME | Exit | Zymeworks Inc. | $0 | – | -4,000 | -100.0% | -0.02% | – |
| TIGR | Exit | UP Financial Holdings | $0 | – | -13,736 | -100.0% | -0.02% | – |
| TMUS | Exit | T-Mobil US Inc | $0 | – | -700 | -100.0% | -0.03% | – |
| SAIL | Exit | Sailpoint Technologies | $0 | – | -1,700 | -100.0% | -0.03% | – |
| ACQR | Exit | Independence Holdings | $0 | – | -9,500 | -100.0% | -0.03% | – |
| JMIA | Exit | Jumia Technologies AG | $0 | – | -9,800 | -100.0% | -0.04% | – |
| PSTX | Exit | Poseida Therapeutics, Inc. | $0 | – | -19,566 | -100.0% | -0.04% | – |
| RLMD | Exit | Relmada Therapeutics, Inc. | $0 | – | -6,000 | -100.0% | -0.05% | – |
| QURE | Exit | uniQure N.V. | $0 | – | -6,766 | -100.0% | -0.05% | – |
| ASLN | Exit | ASLAN Pharmaceuticals Limited | $0 | – | -230,251 | -100.0% | -0.09% | – |
| ROCRW | Exit | Roth CH Acquisition III Co. Warrants | $0 | – | -25,000 | -100.0% | -0.10% | – |
| FB | Exit | Meta Platforms Inc. | $0 | – | -990 | -100.0% | -0.11% | – |
| GLPG | Exit | Galapagos NV | $0 | – | -7,000 | -100.0% | -0.13% | – |
| Exit | Marinus Pharmaceuticals, Inc. | $0 | – | -46,697 | -100.0% | -0.19% | – | |
| TGTX | Exit | TG Therapeutics, Inc. | $0 | – | -33,592 | -100.0% | -0.22% | – |
| Exit | Doma Holdings, Inc. - Warrants | $0 | – | -83,333 | -100.0% | -0.32% | – | |
| ROCR | Exit | Roth CH Acquisition III Co. | $0 | – | -100,000 | -100.0% | -0.34% | – |
| DNMR | Exit | Danimer Scientific, Inc. | $0 | – | -200,000 | -100.0% | -0.58% | – |
| ZGNX | Exit | Zogenix, Inc. | $0 | – | -134,688 | -100.0% | -0.74% | – |
| CLMT | Exit | Calumet Specialty Product @ 7call | $0 | – | -4,727 | -100.0% | -2.12% | – |
| APO | Exit | Apollo Global Management, Inc. | $0 | – | -250,000 | -100.0% | -6.15% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-05-16
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Calumet Specialty Products Partners, LP | 8 | Q3 2023 | 31.5% |
| Alphabet Inc-Cl C | 8 | Q3 2023 | 5.6% |
| DocGo, Inc. | 8 | Q3 2023 | 5.8% |
| Ligand Pharmaceuticals Incorporated | 8 | Q3 2023 | 4.3% |
| Franklin BSP Realty Trust, Inc. | 8 | Q3 2023 | 4.9% |
| Midwest Holding Inc. | 8 | Q3 2023 | 4.1% |
| Coliseum Acquisition Corp.WTS | 8 | Q3 2023 | 2.4% |
| Pfizer Inc. | 8 | Q3 2023 | 3.2% |
| Jazz Pharmaceuticals PLC | 8 | Q3 2023 | 1.5% |
| Vertex Pharmaceuticals, Inc. | 8 | Q3 2023 | 2.1% |
View Knott David M Jr's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Calumet Specialty Products Partners, L.P. | November 08, 2021 | 4,292,200 | 5.4% |
View Knott David M Jr's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-13 |
| 4 | 2023-12-22 |
| SC 13D/A | 2023-12-22 |
| 13F-HR | 2023-11-13 |
| 13F-HR | 2023-08-11 |
| 13F-HR | 2023-05-11 |
| 13F-HR | 2023-02-13 |
| 13F-HR | 2022-11-10 |
| 4 | 2022-09-26 |
| 4 | 2022-09-02 |
View Knott David M Jr's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.